| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ADMAADMA Biologics, Inc. | 4.16B | 17.50 | 21.60 | 65.15% | 42.87% | 48.57% | 2.64% | 0.24 |
| CVACCureVac N.V. | 1.05B | 4.66 | 6.47 | 8.96% | 37.93% | 33.02% | 7.95% | 0.06 |
| DWTXDogwood Therapeutics, Inc. | 83.24M | 2.80 | -0.22 | -49.37% | 0.24 | |||
| ALGSAligos Therapeutics, Inc. | 44.22M | 8.26 | -0.39 | -74.6% | -32.68% | -120.37% | ||
| INOInovio Pharmaceuticals, Inc. | 108.55M | 1.58 | -0.40 | -73.83% | -592.82% | -115.42% | 0.17 | |
| BRNSBarinthus Biotherapeutics plc | 29.81M | 0.73 | -0.47 | 17.66% | -408% | -89.73% | 0.09 | |
| COCPCocrystal Pharma, Inc. | 15.3M | 1.11 | -0.65 | -126.11% | 0.19 | |||
| KLRSKalaris Therapeutics Inc | 165.7M | 8.86 | -0.76 | -170.84% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 48.63M | 351.37M | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | 6.22% | -1% | - | - |
| Cost of Goods Sold | 17K | 17K | 38.02M | 167.21M | 62.39M | 70.09M | 83.37M |
| COGS % of Revenue | - | - | 0.78% | 0.48% | - | - | - |
| Gross Profit | -17K | -17K | 10.61M | 184.16M | -62.39M | -70.09M | -83.37M |
| Gross Margin % | - | - | 0.22% | 0.52% | - | - | - |
| Gross Profit Growth % | - | 0% | 625.12% | 16.36% | -1.34% | -0.12% | -0.19% |
| Operating Expenses | 9.48M | 14.61M | 21.64M | 45.78M | 68.26M | 94.07M | 109.58M |
| OpEx % of Revenue | - | - | 0.44% | 0.13% | - | - | - |
| Selling, General & Admin | 2.8M | 4.44M | 21.64M | 45.78M | 48.71M | 49.92M | 48.85M |
| SG&A % of Revenue | - | - | 0.44% | 0.13% | - | - | - |
| Research & Development | 6.67M | 10.17M | 38.02M | 167.21M | 88.84M | 132.84M | 145.4M |
| R&D % of Revenue | - | - | 0.78% | 0.48% | - | - | - |
| Other Operating Expenses | 0 | 0 | -38.02M | -167.21M | -69.29M | -88.69M | -84.67M |
| Operating Income | -9.48M | -14.61M | -11.03M | 138.38M | -130.65M | -164.16M | -192.95M |
| Operating Margin % | - | - | -0.23% | 0.39% | - | - | - |
| Operating Income Growth % | - | -0.54% | 0.24% | 13.55% | -1.94% | -0.26% | -0.18% |
| EBITDA | -9.46M | -14.59M | -11.01M | 138.41M | -130.39M | -163.75M | -192.53M |
| EBITDA Margin % | - | - | -0.23% | 0.39% | - | - | - |
| EBITDA Growth % | - | -0.54% | 0.25% | 13.57% | -1.94% | -0.26% | -0.18% |
| D&A (Non-Cash Add-back) | 17K | 17K | 19K | 29K | 260K | 416K | 416K |
| EBIT | -9.48M | -14.61M | -11.03M | 138.38M | -111.1M | -120.01M | -132.22M |
| Net Interest Income | 0 | 574K | 83K | 213K | 0 | 29.22M | 25.49M |
| Interest Income | 413K | 574K | 83K | 213K | 11.15M | 29.22M | 25.49M |
| Interest Expense | 0 | 0 | 0 | 0 | 11.15M | 0 | 0 |
| Other Income/Expense | 413K | 574K | 83K | 213K | 11.15M | 29.22M | 25.49M |
| Pretax Income | -9.06M | -14.03M | -10.95M | 138.59M | -119.5M | -134.94M | -167.46M |
| Pretax Margin % | - | - | -0.23% | 0.39% | - | - | - |
| Income Tax | 0 | 0 | 0 | 17.4M | -3.59M | 1.02M | 925K |
| Effective Tax Rate % | 1% | 0.96% | 1% | 0.87% | 0.97% | 1.01% | 1.01% |
| Net Income | -9.06M | -13.46M | -10.95M | 121.19M | -115.91M | -135.96M | -168.38M |
| Net Margin % | - | - | -0.23% | 0.34% | - | - | - |
| Net Income Growth % | - | -0.48% | 0.19% | 12.07% | -1.96% | -0.17% | -0.24% |
| Net Income (Continuing) | -9.06M | -14.03M | -10.95M | 121.19M | -115.91M | -135.96M | -168.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.90 | -0.16 | -0.13 | 1.37 | -1.39 | -1.63 | -2.00 |
| EPS Growth % | - | 0.82% | 0.19% | 11.54% | -2.01% | -0.17% | -0.23% |
| EPS (Basic) | -0.90 | -0.16 | -0.13 | 1.46 | -1.39 | -1.63 | -2.00 |
| Diluted Shares Outstanding | 10.09M | 82.62M | 82.44M | 88.25M | 83.25M | 83.39M | 84.26M |
| Basic Shares Outstanding | 10.09M | 82.62M | 82.44M | 82.82M | 83.25M | 83.39M | 84.26M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 34.7M | 21.91M | 863.48M | 772.4M | 660.92M | 590.46M | 462.36M |
| Cash & Short-Term Investments | 34.49M | 21.66M | 850.12M | 764.38M | 646.71M | 578.11M | 454.72M |
| Cash Only | 34.49M | 21.66M | 850.12M | 764.38M | 646.71M | 143.82M | 64.7M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 434.28M | 390.02M |
| Accounts Receivable | 0 | 0 | 5.82M | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | 43.64 | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 249K | 0 | 0 | 14.21M | 12.35M | 7.63M |
| Total Non-Current Assets | 163K | 163K | 155K | 489K | 5.79M | 4.51M | 2.31M |
| Property, Plant & Equipment | 56K | 41K | 48K | 184K | 4.09M | 3.12M | 2.12M |
| Fixed Asset Turnover | - | - | 1013.19x | 1909.60x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 107K | 107K | 107K | 0 | 198K | 0 | 0 |
| Other Non-Current Assets | 0 | 15K | 0 | 305K | 1.49M | 1.4M | 197K |
| Total Assets | 34.86M | 22.07M | 863.63M | 772.89M | 666.71M | 594.97M | 464.67M |
| Asset Turnover | - | - | 0.06x | 0.45x | - | - | - |
| Asset Growth % | - | -0.37% | 38.13% | -0.11% | -0.14% | -0.11% | -0.22% |
| Total Current Liabilities | 1.76M | 2.44M | 315.8M | 56.88M | 18.48M | 32.38M | 18.6M |
| Accounts Payable | 391K | 548K | 60K | 4.53M | 2.55M | 4.25M | 4.46M |
| Days Payables Outstanding | 8.39K | 11.77K | 0.58 | 9.9 | 14.92 | 22.14 | 19.52 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 200K | 200K | 1000K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 200K | 1.69M | 11.63M | 27.57M | 8.65M | 0 | 7.44M |
| Current Ratio | 19.71x | 9.00x | 2.73x | 13.58x | 35.77x | 18.24x | 24.85x |
| Quick Ratio | 19.71x | 9.00x | 2.73x | 13.58x | 35.77x | 18.24x | 24.85x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 69.26M | 95K | 36K | 5.93M | 7.66M | 7.4M | 7.2M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 2.4M | 1.64M | 842K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 69.26M | 95K | 36K | 5.93M | 5.25M | 5.76M | 6.36M |
| Total Liabilities | 71.02M | 2.53M | 315.83M | 62.81M | 26.14M | 39.78M | 25.8M |
| Total Debt | 0 | 0 | 0 | 197K | 3.12M | 2.4M | 1.64M |
| Net Debt | -34.49M | -21.66M | -850.12M | -764.18M | -643.59M | -141.42M | -63.05M |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | 0.00x | - | - | - |
| Net Debt / EBITDA | - | - | - | -5.52x | - | - | - |
| Interest Coverage | - | - | - | - | -11.72x | - | - |
| Total Equity | -36.16M | 19.54M | 547.8M | 710.08M | 640.57M | 555.19M | 438.87M |
| Equity Growth % | - | 1.54% | 27.03% | 0.3% | -0.1% | -0.13% | -0.21% |
| Book Value per Share | -3.58 | 0.24 | 6.65 | 8.05 | 7.69 | 6.66 | 5.21 |
| Total Shareholders' Equity | -36.16M | 19.54M | 547.8M | 710.08M | 640.57M | 555.19M | 438.87M |
| Common Stock | 10K | 10K | 82K | 83K | 83K | 83K | 84K |
| Retained Earnings | -40.18M | -54.21M | -65.16M | 56.03M | -59.88M | -195.84M | -364.22M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -69.11M | 0 | -863.63M | 0 | -684K | 207K | 233K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.91M | -12.81M | 296.73M | -87M | -120.98M | -85.39M | -135.5M |
| Operating CF Margin % | - | - | 6.1% | -0.25% | - | - | - |
| Operating CF Growth % | - | -0.62% | 24.16% | -1.29% | -0.39% | 0.29% | -0.59% |
| Net Income | -9.06M | -14.03M | -10.95M | 121.19M | -115.91M | -135.96M | -168.38M |
| Depreciation & Amortization | 17K | 17K | 19K | 29K | 260K | 416K | 416K |
| Stock-Based Compensation | 414K | 624K | 7.46M | 39.62M | 46.72M | 49.43M | 51.77M |
| Deferred Taxes | 0 | -501K | 0 | -29.39M | 0 | -48.56M | 0 |
| Other Non-Cash Items | 538K | 501K | 0 | 29.39M | -5.46M | 33.11M | -11.82M |
| Working Capital Changes | 725K | 579K | 300.2M | -247.84M | -46.59M | 16.16M | -7.48M |
| Change in Receivables | 0 | 0 | -5.82M | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -90K | 157K | -488K | 10.29M | -1.98M | 1.7M | 206K |
| Cash from Investing | -12K | -2K | -26K | -4K | -455.41M | 40.3M | 56.1M |
| Capital Expenditures | -12K | -2K | -26K | -4K | -1.94M | 0 | 0 |
| CapEx % of Revenue | - | - | 0% | 0% | - | - | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -453.47K | 0 | 0 |
| Cash from Financing | 27.48M | -15K | 531.75M | 1.47M | 370K | 257K | 267K |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 27.48M | 0 | 0 | 0 | 140K | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -7.92M | -12.82M | 296.71M | -87.01M | -122.92M | -85.39M | -135.5M |
| FCF Margin % | - | - | 6.1% | -0.25% | - | - | - |
| FCF Growth % | - | -0.62% | 24.15% | -1.29% | -0.41% | 0.31% | -0.59% |
| FCF per Share | -0.78 | -0.16 | 3.60 | -0.99 | -1.48 | -1.02 | -1.61 |
| FCF Conversion (FCF/Net Income) | 0.87x | 0.95x | -27.11x | -0.72x | 1.04x | 0.63x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -68.87% | -3.86% | 19.27% | -17.16% | -22.74% | -33.88% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -59.95% | -36.66% |
| Gross Margin | - | - | 21.82% | 52.41% | - | - | - |
| Net Margin | - | - | -22.51% | 34.49% | - | - | - |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | - | - | - | - | -11.72x | - | - |
| FCF Conversion | 0.87x | 0.95x | -27.11x | -0.72x | 1.04x | 0.63x | 0.80x |
| Revenue Growth | - | - | - | 622.49% | -100% | - | - |
Atea Pharmaceuticals, Inc. (AVIR) grew revenue by 0.0% over the past year. Growth has been modest.
Atea Pharmaceuticals, Inc. (AVIR) reported a net loss of $147.0M for fiscal year 2024.
Atea Pharmaceuticals, Inc. (AVIR) has a return on equity (ROE) of -33.9%. Negative ROE indicates the company is unprofitable.
Atea Pharmaceuticals, Inc. (AVIR) had negative free cash flow of $134.2M in fiscal year 2024, likely due to heavy capital investments.